Table IV.
Clinical characteristics at the time of diagnosis according the treatment response.
| Variable | Responders n=17 | Non-responders n=9 | P-value |
|---|---|---|---|
| Clinical symptoms | |||
| Dyspnea, n (%) | 12 (70.6) | 3 (33.3) | 0.103b |
| Chest pain, n (%) | 12 (70.6) | 4 (44.4) | 0.234b |
| Palpitations, n (%) | 3 (17.6) | 4 (44.4) | 0.188b |
| Syncope, n (%) | 3 (17.6) | 4 (44.4) | 0.188b |
| Functional class (NYHA) | |||
| CF-I–II, n (%) | 15 (88.2) | 7 (77.8) | 0.591b |
| CF III–IV, n (%) | 2 (11.8) | 2 (22.2) | 0.591b |
| Physical findings upon exploration | |||
| Cardiac frequency (bpm) median (range) | 90 (30–130) | 67 (40–88) | 0.010a,d |
| Hypotension, n (%) | 2 (11.8) | 0 | 0.529b |
| Rales, n (%) | 6 (35.3) | 1 (11.1) | 0.357b |
| Laboratory | |||
| Maximum troponin, median (range) (ng/ml) | 7.9 (0.01–30) | 3.3 (0.01–13.3) | 0.26a |
| Total CPK maximum, median (range) (U/l) | 806 (56–2,444) | 438 (63–1,690) | 0.38a |
| Total CPK-MB maximum, median (range) (U/l) | 72 (1–301) | 43 (15–138) | 0.445a |
| Electrocardiograph findings | |||
| Prolonged QRS (>120 msec), n (%) | 6 (35.3) | 4 (44.4) | 0.692b |
| AV blockage, n (%) | 4 (23.5) | 2 (22.2) | 0.580b |
| Tachyarrhythmia, n (%) | 4 (23.5) | 6 (66.7) | 0.046b,c |
| Echocardiograph findings | |||
| LVEF (%) median (range) | 35 (13–57) | 60 (31–70) | 0.004a,d |
| LVEF <45%, n (%) | 11 (64.7) | 2 (22.2) | 0.097b |
| Right ventricular dysfunction, n (%) | 7 (41.2) | 0 | 0.057b |
| Ventricular dysfunction, n (%) | 12 (70.6) | 2 (22.2) | 0.038b,c |
| PASP (mmHg) median (range) | 34 (17–50) | 27 (25–40) | 0.181a |
| TAPSE (mm) median (range) | 18 (11–27) | 21.5 (19–26) | 0.016a,c |
a
Mann-Whitney U test.
b
Fisher exact test.
c
P<0.05.
d
P<0.01. NYHA, New York Heart Association; CF, Functional class; bpm, beats per minute; CPK, Creatine phosphokinase; MB, isoform muscle/brain; AV, atrioventricular; LVEF, Left ventricular ejection fraction; PSAP, Pulmonary artery systolic pressure.